CA2131130A1 - Modulation de l'activite cellulaire - Google Patents

Modulation de l'activite cellulaire

Info

Publication number: CA2131130A1
Authority: CA; Canada
Prior art keywords: daltons; hyaluronic acid; fractions; agent; human
Prior art date: 1994-08-30
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002131130A

Other languages

English (en)

Inventor

Samuel Simon Asculai

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Hyal Pharmaceutical Corp

Original Assignee

Hyal Pharmaceutical Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-08-30

Filing date

1994-08-30

Publication date

1996-03-01

1994-08-30 Application filed by Hyal Pharmaceutical Corp filed Critical Hyal Pharmaceutical Corp

1994-08-30 Priority to CA002131130A priority Critical patent/CA2131130A1/fr

1995-08-11 Priority to JP8508371A priority patent/JPH10504828A/ja

1995-08-11 Priority to HU9701507A priority patent/HUT76846A/hu

1995-08-11 Priority to EP95927605A priority patent/EP0778776A1/fr

1995-08-11 Priority to AU31595/95A priority patent/AU3159595A/en

1995-08-11 Priority to IL11491495A priority patent/IL114914A0/xx

1995-08-11 Priority to KR1019970701164A priority patent/KR970705401A/ko

1995-08-11 Priority to PCT/CA1995/000477 priority patent/WO1996006622A1/fr

1995-08-14 Priority to APAP/P/1995/000756A priority patent/AP618A/en

1995-08-29 Priority to CN95116995A priority patent/CN1130532A/zh

1995-08-29 Priority to ZA957223A priority patent/ZA957223B/xx

1996-03-01 Publication of CA2131130A1 publication Critical patent/CA2131130A1/fr

Status Abandoned legal-status Critical Current

Links

230000000694 effects Effects 0.000 title claims abstract description 31
230000001413 cellular effect Effects 0.000 title claims abstract description 28
229920002674 hyaluronan Polymers 0.000 claims abstract description 114
229960003160 hyaluronic acid Drugs 0.000 claims abstract description 108
KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims abstract description 102
229920002385 Sodium hyaluronate Polymers 0.000 claims abstract description 29
229940010747 sodium hyaluronate Drugs 0.000 claims abstract description 29
YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims abstract description 29
102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 claims abstract description 19
108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 claims abstract description 19
150000003839 salts Chemical class 0.000 claims abstract description 19
231100000252 nontoxic Toxicity 0.000 claims abstract description 18
230000003000 nontoxic effect Effects 0.000 claims abstract description 18
238000000034 method Methods 0.000 claims abstract description 17
102100032912 CD44 antigen Human genes 0.000 claims abstract description 14
101000868273 Homo sapiens CD44 antigen Proteins 0.000 claims abstract description 14
150000002148 esters Chemical class 0.000 claims abstract description 14
239000012634 fragment Substances 0.000 claims abstract description 14
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 12
241000722985 Fidia Species 0.000 claims abstract description 11
102100027735 Hyaluronan mediated motility receptor Human genes 0.000 claims abstract description 11
108010003425 hyaluronan-mediated motility receptor Proteins 0.000 claims abstract description 11
-1 HARLEC Proteins 0.000 claims abstract description 10
239000008223 sterile water Substances 0.000 claims abstract description 9
239000003937 drug carrier Substances 0.000 claims abstract description 5
239000003814 drug Substances 0.000 claims description 40
229940079593 drug Drugs 0.000 claims description 29
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 20
201000010099 disease Diseases 0.000 claims description 20
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 20
CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims description 16
238000011282 treatment Methods 0.000 claims description 16
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 13
239000003795 chemical substances by application Substances 0.000 claims description 12
230000000699 topical effect Effects 0.000 claims description 11
239000003242 anti bacterial agent Substances 0.000 claims description 10
239000002246 antineoplastic agent Substances 0.000 claims description 10
108020003175 receptors Proteins 0.000 claims description 10
FBWNMEQMRUMQSO-UHFFFAOYSA-N tergitol NP-9 Chemical compound CCCCCCCCCC1=CC=C(OCCOCCOCCOCCOCCOCCOCCOCCOCCO)C=C1 FBWNMEQMRUMQSO-UHFFFAOYSA-N 0.000 claims description 10
229960000905 indomethacin Drugs 0.000 claims description 8
239000008194 pharmaceutical composition Substances 0.000 claims description 8
229940124597 therapeutic agent Drugs 0.000 claims description 7
241000792859 Enema Species 0.000 claims description 6
239000006071 cream Substances 0.000 claims description 6
239000007920 enema Substances 0.000 claims description 6
229940095399 enema Drugs 0.000 claims description 6
108010036941 Cyclosporins Proteins 0.000 claims description 5
ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 5
229940123457 Free radical scavenger Drugs 0.000 claims description 5
208000010159 IgA glomerulonephritis Diseases 0.000 claims description 5
206010021263 IgA nephropathy Diseases 0.000 claims description 5
102000000588 Interleukin-2 Human genes 0.000 claims description 5
108010002350 Interleukin-2 Proteins 0.000 claims description 5
ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 claims description 5
CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims description 5
229930003268 Vitamin C Natural products 0.000 claims description 5
230000000202 analgesic effect Effects 0.000 claims description 5
239000003945 anionic surfactant Substances 0.000 claims description 5
229940124599 anti-inflammatory drug Drugs 0.000 claims description 5
229940088710 antibiotic agent Drugs 0.000 claims description 5
239000003429 antifungal agent Substances 0.000 claims description 5
229940121375 antifungal agent Drugs 0.000 claims description 5
239000003443 antiviral agent Substances 0.000 claims description 5
235000010323 ascorbic acid Nutrition 0.000 claims description 5
239000011668 ascorbic acid Substances 0.000 claims description 5
229960005070 ascorbic acid Drugs 0.000 claims description 5
229960000686 benzalkonium chloride Drugs 0.000 claims description 5
CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims description 5
229940124630 bronchodilator Drugs 0.000 claims description 5
239000003093 cationic surfactant Substances 0.000 claims description 5
YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 claims description 5
229960001927 cetylpyridinium chloride Drugs 0.000 claims description 5
239000003433 contraceptive agent Substances 0.000 claims description 5
230000002254 contraceptive effect Effects 0.000 claims description 5
229930182912 cyclosporin Natural products 0.000 claims description 5
229940127089 cytotoxic agent Drugs 0.000 claims description 5
206010012601 diabetes mellitus Diseases 0.000 claims description 5
239000002934 diuretic Substances 0.000 claims description 5
229940030606 diuretics Drugs 0.000 claims description 5
ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 claims description 5
229960003883 furosemide Drugs 0.000 claims description 5
230000003779 hair growth Effects 0.000 claims description 5
229960003444 immunosuppressant agent Drugs 0.000 claims description 5
239000003018 immunosuppressive agent Substances 0.000 claims description 5
229940079322 interferon Drugs 0.000 claims description 5
208000028867 ischemia Diseases 0.000 claims description 5
229960004752 ketorolac Drugs 0.000 claims description 5
OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 claims description 5
229960003632 minoxidil Drugs 0.000 claims description 5
229960002009 naproxen Drugs 0.000 claims description 5
CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims description 5
239000002736 nonionic surfactant Substances 0.000 claims description 5
229940087419 nonoxynol-9 Drugs 0.000 claims description 5
229920004918 nonoxynol-9 Polymers 0.000 claims description 5
239000002516 radical scavenger Substances 0.000 claims description 5
230000003637 steroidlike Effects 0.000 claims description 5
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical class OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 5
230000002792 vascular Effects 0.000 claims description 5
235000019154 vitamin C Nutrition 0.000 claims description 5
239000011718 vitamin C Substances 0.000 claims description 5
239000000203 mixture Substances 0.000 claims description 3
230000005764 inhibitory process Effects 0.000 claims description 2
210000004027 cell Anatomy 0.000 description 20
210000001519 tissue Anatomy 0.000 description 13
102000005962 receptors Human genes 0.000 description 8
KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 6
229940099552 hyaluronan Drugs 0.000 description 6
239000000243 solution Substances 0.000 description 6
241000709661 Enterovirus Species 0.000 description 5
210000003491 skin Anatomy 0.000 description 5
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 4
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
229960001138 acetylsalicylic acid Drugs 0.000 description 4
230000008033 biological extinction Effects 0.000 description 4
230000006378 damage Effects 0.000 description 4
208000006011 Stroke Diseases 0.000 description 3
239000000061 acid fraction Substances 0.000 description 3
230000003511 endothelial effect Effects 0.000 description 3
210000004185 liver Anatomy 0.000 description 3
210000004877 mucosa Anatomy 0.000 description 3
230000002265 prevention Effects 0.000 description 3
230000004044 response Effects 0.000 description 3
159000000000 sodium salts Chemical class 0.000 description 3
MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
102000016289 Cell Adhesion Molecules Human genes 0.000 description 2
108010067225 Cell Adhesion Molecules Proteins 0.000 description 2
108010001857 Cell Surface Receptors Proteins 0.000 description 2
AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 2
IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
229920002683 Glycosaminoglycan Polymers 0.000 description 2
241000430519 Human rhinovirus sp. Species 0.000 description 2
OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 2
OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 2
MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 2
206010028980 Neoplasm Diseases 0.000 description 2
150000001413 amino acids Chemical class 0.000 description 2
MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
210000002889 endothelial cell Anatomy 0.000 description 2
229960002442 glucosamine Drugs 0.000 description 2
229940097043 glucuronic acid Drugs 0.000 description 2
229910001385 heavy metal Inorganic materials 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
230000028709 inflammatory response Effects 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
208000014674 injury Diseases 0.000 description 2
229910052742 iron Inorganic materials 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
102000006240 membrane receptors Human genes 0.000 description 2
229950006780 n-acetylglucosamine Drugs 0.000 description 2
201000009240 nasopharyngitis Diseases 0.000 description 2
230000008569 process Effects 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
238000012360 testing method Methods 0.000 description 2
230000008733 trauma Effects 0.000 description 2
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
241000282709 Aotus trivirgatus Species 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
241000282412 Homo Species 0.000 description 1
108010003272 Hyaluronate lyase Proteins 0.000 description 1
102000001974 Hyaluronidases Human genes 0.000 description 1
102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
206010061137 Ocular toxicity Diseases 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
206010044245 Toxic optic neuropathy Diseases 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
210000002159 anterior chamber Anatomy 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
210000001742 aqueous humor Anatomy 0.000 description 1
238000003556 assay Methods 0.000 description 1
230000037396 body weight Effects 0.000 description 1
239000005388 borosilicate glass Substances 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
230000021164 cell adhesion Effects 0.000 description 1
210000003161 choroid Anatomy 0.000 description 1
230000015271 coagulation Effects 0.000 description 1
238000005345 coagulation Methods 0.000 description 1
210000004087 cornea Anatomy 0.000 description 1
210000000695 crystalline len Anatomy 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
150000002016 disaccharides Chemical class 0.000 description 1
230000009429 distress Effects 0.000 description 1
238000001035 drying Methods 0.000 description 1
239000002158 endotoxin Substances 0.000 description 1
210000002615 epidermis Anatomy 0.000 description 1
210000002919 epithelial cell Anatomy 0.000 description 1
238000009472 formulation Methods 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
239000003292 glue Substances 0.000 description 1
229960002773 hyaluronidase Drugs 0.000 description 1
230000008595 infiltration Effects 0.000 description 1
238000001764 infiltration Methods 0.000 description 1
210000004969 inflammatory cell Anatomy 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
210000000554 iris Anatomy 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
239000007788 liquid Substances 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
239000000463 material Substances 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
230000001394 metastastic effect Effects 0.000 description 1
206010061289 metastatic neoplasm Diseases 0.000 description 1
230000000813 microbial effect Effects 0.000 description 1
230000002906 microbiologic effect Effects 0.000 description 1
230000005012 migration Effects 0.000 description 1
238000013508 migration Methods 0.000 description 1
230000004899 motility Effects 0.000 description 1
230000000926 neurological effect Effects 0.000 description 1
210000000440 neutrophil Anatomy 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
231100000956 nontoxicity Toxicity 0.000 description 1
231100000327 ocular toxicity Toxicity 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
239000002245 particle Substances 0.000 description 1
231100000915 pathological change Toxicity 0.000 description 1
230000036285 pathological change Effects 0.000 description 1
239000002510 pyrogen Substances 0.000 description 1
238000011084 recovery Methods 0.000 description 1
210000000664 rectum Anatomy 0.000 description 1
210000001525 retina Anatomy 0.000 description 1
238000009781 safety test method Methods 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
229940049529 sodium hyaluronate 20 mg/ml Drugs 0.000 description 1
230000008685 targeting Effects 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
231100000041 toxicology testing Toxicity 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Molecular Biology (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Dermatology (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

CA002131130A 1991-07-03 1994-08-30 Modulation de l'activite cellulaire Abandoned CA2131130A1 (fr)

Priority Applications (11)

Application Number	Priority Date	Filing Date	Title
CA002131130A CA2131130A1 (fr)	1994-08-30	1994-08-30	Modulation de l'activite cellulaire
JP8508371A JPH10504828A (ja)	1994-08-30	1995-08-11	細胞活性調整のためのヒアルロン酸およびその誘導体
HU9701507A HUT76846A (en)	1994-08-30	1995-08-11	Hyaluronic acid and derivatives for modulation of cellular activity
EP95927605A EP0778776A1 (fr)	1994-08-30	1995-08-11	Acide hyaluronique et derives destines a la modulation de l'activite cellulaire
AU31595/95A AU3159595A (en)	1994-08-30	1995-08-11	Hyaluronic acid and derivatives for modulation of cellular activity
IL11491495A IL114914A0 (en)	1994-08-30	1995-08-11	Modulation of cellular activity
KR1019970701164A KR970705401A (ko)	1994-08-30	1995-08-11	세포활성의 조정용 히알루론산과 그 유도체(hyaluronic acid and derivatives for modulation of cellular activity)
PCT/CA1995/000477 WO1996006622A1 (fr)	1991-07-03	1995-08-11	Acide hyaluronique et derives destines a la modulation de l'activite cellulaire
APAP/P/1995/000756A AP618A (en)	1994-08-30	1995-08-14	Modulation of cellular activity by administering a form of hyaluronic acid.
CN95116995A CN1130532A (zh)	1994-08-30	1995-08-29	细胞活性调节
ZA957223A ZA957223B (en)	1994-08-30	1995-08-29	Modulation of cellular activity

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CA002131130A CA2131130A1 (fr)	1994-08-30	1994-08-30	Modulation de l'activite cellulaire

Publications (1)

Publication Number	Publication Date
CA2131130A1 true CA2131130A1 (fr)	1996-03-01

Family

ID=4154258

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002131130A Abandoned CA2131130A1 (fr)	1991-07-03	1994-08-30	Modulation de l'activite cellulaire

Country Status (2)

Country	Link
CA (1)	CA2131130A1 (fr)
ZA (1)	ZA957223B (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2003070256A1 (fr) *	2002-02-15	2003-08-28	Research Development Foundation	Tranduction adenovirale induite par l'acide hyaluronique

1994
- 1994-08-30 CA CA002131130A patent/CA2131130A1/fr not_active Abandoned
1995
- 1995-08-29 ZA ZA957223A patent/ZA957223B/xx unknown

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2003070256A1 (fr) *	2002-02-15	2003-08-28	Research Development Foundation	Tranduction adenovirale induite par l'acide hyaluronique
US7144870B2 (en)	2002-02-15	2006-12-05	Research Development Foundation	Hyaluronic acid mediated adenoviral transduction
CN1309392C (zh) *	2002-02-15	2007-04-11	研究发展基金会	透明质酸介导的腺病毒转导

Also Published As

Publication number	Publication date
ZA957223B (en)	1996-04-01

Legal Events

Date	Code	Title	Description
1995-08-02	EEER	Examination request
2000-02-25	FZDE	Dead

Publication	Publication Date	Title
AP618A (en)	1997-10-10	Modulation of cellular activity by administering a form of hyaluronic acid.
US5614506A (en)	1997-03-25	Use of hyaluronic acid and forms to prevent arterial restenosis
US6537978B1 (en)	2003-03-25	Oral administration of effective amounts of forms of hyaluronic acid
CA2122519C (fr)	2001-02-20	Traitement du cancer et prevention des metastases
HU220758B1 (hu)	2002-05-28	Eljárás hialuronsavat és nem szteroid gyulladásgátlót tartalmazó, rák kezelésére alkalmas gyógyászati készítmények előállítására
US20030036525A1 (en)	2003-02-20	Use of hyaluronan in gene therapy
US5834444A (en)	1998-11-10	Hyaluronic acid and salts thereof inhibit arterial restenosis
CA2175282A1 (fr)	1997-10-30	Utilisation de diverses formes d'acide hyaluronique (ah) pour le traitement du cancer
HUT74462A (en)	1996-12-30	Compositions for inhibition of angiogenesis, containing hyaluronic acid and nonsteroidal anti-inflammatory agents
US5847002A (en)	1998-12-08	Compositions, for inhibition, control and regression of angiogenesis, containing hyaluronic acid and NSAID
EP0874624B1 (fr)	2003-12-03	Ligands des recepteurs a l'acide hyaluronique et leur utilisation dans le traitement des tumeurs et de la restenose
CA2208924A1 (fr)	1999-01-09	Utilisation reduite de paclitaxel grace a l'hyaluronan
US5817642A (en)	1998-10-06	Clearing of atherosclerosis
AP448A (en)	1996-01-18	Use of hyaluronic acid and forms to prevent arterial restenosis.
JPH10287570A (ja)	1998-10-27	角膜障害症治癒促進剤
US5817644A (en)	1998-10-06	Targeting of dosages of medicine and therapeutic agents
CA2131130A1 (fr)	1996-03-01	Modulation de l'activite cellulaire
AU727001B2 (en)	2000-11-30	Targeting of dosages of medicine and therapeutic agents and other glycosaminoglycans (GAGS)
EP0758246A1 (fr)	1997-02-19	Composition pharmaceutique comprenant de l'acide hyaluronique et destinee a eliminer l'arteriosclerose
CA2164260C (fr)	2001-10-09	Methode de ciblage pour medicaments et agents therapeutiques
CA2156013A1 (fr)	1997-02-15	Modulation de l'activite cellulaire
CA2167044C (fr)	2001-08-07	Administration par voie orale de quantites efficaces de certaines formes d'acide hyaluronique
CA2145605A1 (fr)	1996-09-28	Modulation de l'activite cellulaire
CA2166154A1 (fr)	1997-06-28	Agents liants et utilisation correspondante
CA2106695C (fr)	2000-01-18	Acide hyaluronique et composes pour la prevention de la restenose arterielle